Oncopole Claudius Regaud

Oncopole Claudius Regaud’s Medical Oncology department leads extensive research on solid tumors, aiming to test innovative therapies and improve patient outcomes across multiple cancer types.

• Advanced breast cancer, including hormone‑receptor‑positive and HER2‑negative subtypes
• Non‑small cell lung cancer (NSCLC) and rare thoracic malignancies
• Gastro‑intestinal cancers such as colorectal, pancreatic, and gastric adenocarcinoma
• Renal cell carcinoma and other kidney‑related neoplasms
• Metastatic melanoma and cutaneous skin cancers

Over 400 active trials involve more than 300 investigators, reflecting a strong commitment to advancing treatment options for patients with advanced solid cancers.

The site conducts a broad portfolio of studies on blood‑borne cancers, focusing on novel agents and transplantation strategies to enhance survival and quality of life.

• Acute myeloid leukemia (AML) and related myelodysplastic syndromes
• Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)
• Multiple myeloma, including transplant‑ineligible and relapsed disease
• Aggressive B‑cell non‑Hodgkin lymphomas and diffuse large B‑cell lymphoma
• Peripheral T‑cell lymphoma and other rare lymphoid disorders

These trials evaluate targeted therapies, immunotherapies, and stem‑cell transplantation to improve remission rates and reduce treatment‑related toxicity.

A core focus at the centre is the development of precision medicine approaches, integrating molecular profiling with immunotherapeutic agents to treat resistant cancers.

• Checkpoint inhibitors combined with chemotherapy or anti‑angiogenic drugs
• PARP inhibitors for BRCA‑mutated breast and ovarian cancers
• FGFR, ALK, ROS1, and BRAF targeted agents across multiple tumor types
• Antibody‑drug conjugates for HER2‑low and HER2‑positive malignancies
• Cellular therapies such as CAR‑T and engineered T‑cell products for hematologic cancers

By linking genomic alterations to specific drugs, the site seeks to personalize treatment and accelerate regulatory approval pathways.

Research at Oncopole Claudius Regaud includes advanced diagnostic techniques that guide therapeutic decisions and monitor disease progression.

• 18F‑FES PET/CT for assessing estrogen‑receptor activity in breast cancer
• ctDNA surveillance for early detection of molecular relapse
• Multiplex next‑generation sequencing panels for tumor mutational profiling
• Radiomic analysis of MRI and CT scans to predict treatment response
• Biomarker validation for immune checkpoint efficacy across cancer types

These studies aim to refine patient selection, reduce unnecessary toxicity, and support adaptive trial designs.

The centre dedicates resources to rare and pediatric cancers, offering patients access to cutting‑edge trials that would otherwise be unavailable.

• Pediatric medulloblastoma and high‑grade gliomas
• Rare sarcomas such as chondrosarcoma and osteosarcoma
• Germ‑cell tumors and testicular cancers with limited standard options
• Peritoneal mesothelioma and thymic malignancies
• Rare endocrine tumors including pheochromocytoma and paraganglioma

Collaborative networks and molecular screening enable enrollment in international protocols focused on efficacy and safety in these underserved populations.

A substantial portion of the trial portfolio addresses female urogenital and male urogenital diseases, exploring novel systemic and localized therapies.

• High‑grade serous ovarian, fallopian tube and primary peritoneal cancers
• Endometrial carcinoma, including mismatch‑repair deficient subtypes
• Advanced prostate cancer, both hormone‑sensitive and castration‑resistant forms
• Muscle‑invasive bladder cancer and upper urinary tract urothelial carcinoma
• Cervical and vulvar cancers with targeted or immunotherapeutic approaches

Trials evaluate combination regimens, maintenance strategies, and biomarker‑driven therapies to improve survival and preserve organ function.